Product image of Metoject (Methotrexate) supplied by GNH India

Metoject

Active Ingredient:
Methotrexate
Origin:
EU

Metoject (Methotrexate)

Methotrexate, the active ingredient in Metoject, is an antimetabolite (folate antagonist) presented as a subcutaneous injection for subcutaneous use. It is employed as an immunosuppressant and antineoplastic agent in a range of autoimmune and cancer conditions.
GNH India supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful for several inflammatory and malignant diseases.

  • Rheumatoid arthritis: reduces joint inflammation and slows disease progression.
  • Psoriasis: diminishes skin lesions and plaque formation.
  • Acute lymphoblastic leukemia: interferes with leukemic cell proliferation.
  • Non‑Hodgkin lymphoma: induces cytotoxicity in malignant lymphocytes.
  • Ectopic pregnancy: halts trophoblastic growth to allow non‑surgical resolution.

How It Works

  • Methotrexate inhibits dihydrofolate reductase, preventing the regeneration of tetrahydrofolate needed for purine and pyrimidine synthesis. This blockade reduces DNA, RNA and protein production, leading to cytotoxic effects on rapidly dividing cells and suppressing immune cell activation, which underlies its antineoplastic and immunosuppressive actions.

Side Effects

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea or vomiting: mild to moderate gastrointestinal upset.
  • Fatigue: persistent tiredness unrelated to activity level.
  • Oral mucositis: soreness or ulceration of the mouth lining.
  • Elevated liver enzymes: mild hepatic irritation detectable on labs.
  • Alopecia: temporary thinning or loss of scalp hair.
  • Skin rash: mild erythema or itching.

Serious or Rare Side Effects

  • Bone marrow suppression: pancytopenia leading to infection risk.
  • Pulmonary toxicity: interstitial pneumonitis presenting with cough and dyspnea.
  • Severe hepatotoxicity: fibrosis or cirrhosis with prolonged use.
  • Renal impairment: acute kidney injury due to precipitation of drug crystals.
  • Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks.

  • Pregnancy contraindication: avoid use in pregnancy due to teratogenicity.
  • Breastfeeding restriction: do not breastfeed while receiving methotrexate.
  • Renal function monitoring: adjust dose if creatinine clearance is reduced.
  • Hepatic monitoring: perform regular liver function tests.
  • Infection vigilance: monitor for signs of immunosuppression.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Methotrexate interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate serum levels and risk of toxicity.
  • Proton pump inhibitors (e.g., omeprazole): may reduce renal clearance, heightening adverse effects.
  • Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely)

  • Penicillins (high‑dose): may modestly increase methotrexate concentrations.
  • Sulfonamides: can impair renal elimination.
  • Live vaccines: risk of uncontrolled infection due to immunosuppression.

Frequently Asked Questions

Metoject, containing methotrexate, is prescribed for several autoimmune and oncologic conditions, including rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and ectopic pregnancy. It works by suppressing abnormal immune activity and inhibiting the growth of rapidly dividing cells.

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption reduces the synthesis of DNA, RNA and proteins, leading to decreased proliferation of immune cells and cancer cells, thereby providing anti‑inflammatory and cytotoxic effects.

The specific dose of Metoject is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Healthcare providers calculate the appropriate regimen and adjust it according to therapeutic response and laboratory monitoring.

Metoject is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended for breastfeeding mothers because methotrexate can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the Metoject product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with biologic agents such as TNF‑α inhibitors, methotrexate (Metoject) is a small‑molecule drug that can be administered subcutaneously and is generally less expensive. It offers broad immunosuppressive activity but may have a higher incidence of hepatic and hematologic side effects, requiring regular laboratory monitoring.

Metoject should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods, as potency may be reduced.

Metoject is given by subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to minimize local irritation. Administration is performed by a healthcare professional or a trained patient following aseptic technique and proper disposal of sharps.

The most serious risks include bone marrow suppression leading to severe infections, pulmonary toxicity such as interstitial pneumonitis, and significant liver injury that can progress to fibrosis or cirrhosis. Early detection through regular blood tests and clinical monitoring is essential to mitigate these hazards.

Metoject is contraindicated in pregnant women, breastfeeding mothers, and patients with severe renal or hepatic impairment. It should also be avoided in individuals with known hypersensitivity to methotrexate or any component of the formulation, and in patients receiving certain interacting medications without close supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methotrexate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT